519 related articles for article (PubMed ID: 18802361)
41. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
Varney VA; Tabbah K; Mavroleon G; Frew AJ
Clin Exp Allergy; 2003 Aug; 33(8):1076-82. PubMed ID: 12911781
[TBL] [Abstract][Full Text] [Related]
42. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
Lue KH; Lin YH; Sun HL; Lu KH; Hsieh JC; Chou MC
Pediatr Allergy Immunol; 2006 Sep; 17(6):408-15. PubMed ID: 16925685
[TBL] [Abstract][Full Text] [Related]
43. Topical nasal immunotherapy. Immunologic response of IgE in nasal secretion after immunotherapy with Dermatophagoides pteronyssinus.
Martín Mateos MA; Monferrer R; Muñoz López F
Allergol Immunopathol (Madr); 1990; 18(4):223-8. PubMed ID: 2264553
[TBL] [Abstract][Full Text] [Related]
44. The effect of house dust mite specific immunotherapy on cysteinyl leukotriene production by blood leukocytes in subjects with perennial allergic rhinitis and asthma.
Saraçlar Y; Sekerel BE; Kalayci O; Adalioğlu G; Tuncer A
J Investig Allergol Clin Immunol; 1998; 8(2):98-104. PubMed ID: 9615303
[TBL] [Abstract][Full Text] [Related]
45. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment.
de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC
BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864
[TBL] [Abstract][Full Text] [Related]
46. Changes in serum specific IgG4 and IgG4/ IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial.
Tseng SH; Fu LS; Nong BR; Weng JD; Shyur SD
Asian Pac J Allergy Immunol; 2008; 26(2-3):105-12. PubMed ID: 19054928
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis.
Tahamiler R; Saritzali G; Canakcioglu S; Ozcora E; Dirican A
ORL J Otorhinolaryngol Relat Spec; 2008; 70(3):144-50. PubMed ID: 18391573
[TBL] [Abstract][Full Text] [Related]
48. Olerance of a cluster schedule with a house dust mite extract quantified in mass units: multicentre study.
Tabar AI; Fernández-Távora L; Alonso R; Castillo R; Cisteró-Bahima A; de la Torre-Morin F; Fernández J; García-Figueroa BE; Fernández S; García-González JJ; García-Robaina JC; Moreno F; Lobatón P; Sánchez-Machín I; de la Torre-Martínez F
J Investig Allergol Clin Immunol; 2004; 14(3):193-7. PubMed ID: 15552712
[TBL] [Abstract][Full Text] [Related]
49. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one.
Mauro M; Russello M; Alesina R; Sillano V; Alessandrini A; Dama A; Passalacqua G; Senna G
Eur Ann Allergy Clin Immunol; 2006 Jan; 38(1):31-4. PubMed ID: 16544586
[TBL] [Abstract][Full Text] [Related]
50. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
51. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites.
Roger A; Justicia JL; Navarro LÁ; Eseverri JL; Ferrès J; Malet A; Alvà V
Int Arch Allergy Immunol; 2011; 154(1):69-75. PubMed ID: 20664280
[TBL] [Abstract][Full Text] [Related]
52. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study.
Werfel T; Breuer K; Ruéff F; Przybilla B; Worm M; Grewe M; Ruzicka T; Brehler R; Wolf H; Schnitker J; Kapp A
Allergy; 2006 Feb; 61(2):202-5. PubMed ID: 16409197
[TBL] [Abstract][Full Text] [Related]
53. [Serum eosinophil cationic protein (ECP) in patients with perennial rhinitis and atopic dermatitis, allergic to house dust mites].
Damps-Konstańska I; Gruchała-Niedoszytko M; Wilkowska A; Glén J; Konstański Z; Jassem E; Słomiński JM
Pol Merkur Lekarski; 2005 Dec; 19(114):765-8. PubMed ID: 16521419
[TBL] [Abstract][Full Text] [Related]
54. Long-term immunotherapy for perennial allergic rhinitis: relationship of specific IgG levels to skin-prick test results and clinical symptoms and signs.
Tahamiler R; Canakcioglu S; Yilmaz S; Isildak H
Ear Nose Throat J; 2008 Dec; 87(12):E29. PubMed ID: 19105132
[TBL] [Abstract][Full Text] [Related]
55. A comparative study of the clinical efficacy of immunotherapy and conventional pharmacological treatment for patients with perennial allergic rhinitis.
Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Washio Y; Yamada K; Sakamoto H; Nasako Y; Hayashi M; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():102-12. PubMed ID: 9879409
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy evaluation of specific immunotherapy with standardized dermatophagoides pteronyssinus extract for allergic rhinitis accompanied with asthma].
Chen J; Kong W; Xiang J; Shu H; Shi Q; Tan H; Lu Z; Zhou Y; Zhang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Jan; 24(2):57-9. PubMed ID: 20306851
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
Caramia G; Franceschini F; Cimarelli ZA; Ciucchi MS; Gagliardini R; Ruffini E
Allerg Immunol (Paris); 1996 Nov; 28(9):308-10. PubMed ID: 8986246
[TBL] [Abstract][Full Text] [Related]
58. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy.
Silvestri M; Spallarossa D; Battistini E; Sabatini F; Pecora S; Parmiani S; Rossi GA
J Investig Allergol Clin Immunol; 2002; 12(1):52-9. PubMed ID: 12109533
[TBL] [Abstract][Full Text] [Related]
59. Clinical efficacy of halophilic lactic acid bacterium Tetragenococcus halophilus Th221 from soy sauce moromi for perennial allergic rhinitis.
Nishimura I; Igarashi T; Enomoto T; Dake Y; Okuno Y; Obata A
Allergol Int; 2009 Jun; 58(2):179-85. PubMed ID: 19240374
[TBL] [Abstract][Full Text] [Related]
60. Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up.
Dokic D; Schnitker J; Narkus A; Cromwell O; Frank E
Prilozi; 2005 Dec; 26(2):113-29. PubMed ID: 16400234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
